Literature DB >> 11562465

Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics.

A Gonçalves1, D Braguer, K Kamath, L Martello, C Briand, S Horwitz, L Wilson, M A Jordan.   

Abstract

Microtubule dynamics are crucial for mitotic spindle assembly and chromosome movement. Suppression of dynamics by Taxol appears responsible for the drug's potent ability to inhibit mitosis and cell proliferation. Although Taxol is an important chemotherapeutic agent, development of resistance limits its efficacy. To examine the role of microtubule dynamics in Taxol resistance, we measured the dynamic instability of individual rhodamine-labeled microtubules in Taxol-sensitive and -resistant living human cancer cells. Taxol-resistant A549-T12 and -T24 cell lines were selected from a human lung carcinoma cell line, A549. They are, respectively, 9- and 17-fold resistant to Taxol and require low concentrations of Taxol for proliferation. We found that microtubule dynamic instability was significantly increased in the Taxol-resistant cells. For example, with A549-T12 cells in the absence of added Taxol, microtubule dynamicity increased 57% as compared with A549 cells. The length and rate of shortening excursions increased 75 and 59%, respectively. These parameters were further increased in A549-T24 cells, with overall dynamicity increasing by 167% compared with parental cells. Thus, the decreased Taxol-sensitivity of these cells can be explained by their increased microtubule dynamics. When grown without Taxol, A549-T12 cells were blocked at the metaphase/anaphase transition and displayed abnormal mitotic spindles with uncongressed chromosomes. In the presence of 2-12 nM Taxol, the cells grew normally, suggesting that mitotic block resulted from excessive microtubule dynamics. These results indicate that microtubule dynamics play an important role in Taxol resistance, and that both excessively rapid dynamics and suppressed dynamics impair mitotic spindle function and inhibit proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562465      PMCID: PMC58799          DOI: 10.1073/pnas.191388598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.

Authors:  C Dumontet; B I Sikic
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

2.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.

Authors:  P Giannakakou; D L Sackett; Y K Kang; Z Zhan; J T Buters; T Fojo; M S Poruchynsky
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

Review 4.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy.

Authors:  M A Jordan; L Wilson
Journal:  Curr Opin Cell Biol       Date:  1998-02       Impact factor: 8.382

Review 5.  Cell cycle checkpoints: arresting progress in mitosis.

Authors:  G J Gorbsky
Journal:  Bioessays       Date:  1997-03       Impact factor: 4.345

6.  Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance.

Authors:  M Haber; C A Burkhart; D L Regl; J Madafiglio; M D Norris; S B Horwitz
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

7.  Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833.

Authors:  J P Jaffrézou; C Dumontet; W B Derry; G Durán; K G Chen; E Tsuchiya; L Wilson; M A Jordan; B I Sikic
Journal:  Oncol Res       Date:  1995       Impact factor: 5.574

8.  Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

Authors:  C Dumontet; G E Duran; K A Steger; L Beketic-Oreskovic; B I Sikic
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

9.  Vinblastine suppresses dynamics of individual microtubules in living interphase cells.

Authors:  R Dhamodharan; M A Jordan; D Thrower; L Wilson; P Wadsworth
Journal:  Mol Biol Cell       Date:  1995-09       Impact factor: 4.138

10.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.

Authors:  M A Jordan; K Wendell; S Gardiner; W B Derry; H Copp; L Wilson
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

View more
  87 in total

1.  Paclitaxel-dependent cell lines reveal a novel drug activity.

Authors:  Anutosh Ganguly; Hailing Yang; Fernando Cabral
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

Review 2.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

3.  beta-Tubulin C354 mutations that severely decrease microtubule dynamics do not prevent nuclear migration in yeast.

Authors:  Mohan L Gupta; Claudia J Bode; Douglas A Thrower; Chad G Pearson; Kathy A Suprenant; Kerry S Bloom; Richard H Himes
Journal:  Mol Biol Cell       Date:  2002-08       Impact factor: 4.138

4.  Expression of the SEPT9_i4 isoform confers resistance to microtubule-interacting drugs.

Authors:  Alex D Chacko; Simon S McDade; Severine Chanduloy; Stewart W Church; Richard Kennedy; John Price; Peter A Hall; S E Hilary Russell
Journal:  Cell Oncol (Dordr)       Date:  2012-01-26       Impact factor: 6.730

5.  Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.

Authors:  Adam I Marcus; Ulf Peters; Shala L Thomas; Sarah Garrett; Amelia Zelnak; Tarun M Kapoor; Paraskevi Giannakakou
Journal:  J Biol Chem       Date:  2005-01-13       Impact factor: 5.157

6.  Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2.

Authors:  C Muñoz-Fontela; L Marcos-Villar; F Hernandez; P Gallego; E Rodriguez; J Arroyo; S-J Gao; J Avila; C Rivas
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Authors:  Diego Luis-Ravelo; Iker Antón; Carolina Zandueta; Karmele Valencia; María-José Pajares; Jackeline Agorreta; Luis Montuenga; Silvestre Vicent; Ignacio I Wistuba; Javier De Las Rivas; Fernando Lecanda
Journal:  Mol Oncol       Date:  2013-11-12       Impact factor: 6.603

8.  Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; N Pajuelo-Lozano; B Jiménez; R Perona; I Sánchez-Pérez
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.

Authors:  Seneha Santoshi; Naresh Kumar Manchukonda; Charu Suri; Manya Sharma; Balasubramanian Sridhar; Silja Joseph; Manu Lopus; Srinivas Kantevari; Iswar Baitharu; Pradeep Kumar Naik
Journal:  J Comput Aided Mol Des       Date:  2014-12-07       Impact factor: 3.686

10.  Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.

Authors:  Larissa A Korde; Lara Lusa; Lisa McShane; Peter F Lebowitz; LuAnne Lukes; Kevin Camphausen; Joel S Parker; Sandra M Swain; Kent Hunter; Jo Anne Zujewski
Journal:  Breast Cancer Res Treat       Date:  2010-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.